World Health Organization Says “We’re in a Wound Pandemic”

FOR IMMEDIATE RELEASE

DATELINE: July 17, 2022 Lake Forest California

This Release relates to an article published in the C-Street Advisors regarding a recent study by the World Health Organization and the National Institutes of Health examining the rising concern over recalcitrant wound growth statistics. The article was written by Dr. Daniel Rastien who is the CEO of Cassderma RX, one of the medical technologies targeted by PFD Capital Partners, INC for its PFDMOF3001 Opportunity Fund, LLC (PFDMOF3001). Dr. Rasiten and Cassderma RX are the developers of a new innovative solution for treating a variety of recalcitrant wound issues and are poised to be a leading player in addressing the growing concern in this area.

Announced today by Robert Pryke, PFD Capital Partners, LLC Co-founder, Director, CTO, and PFDMOF3001 Co-manager.
PFD is a lead investor through the PFDMOF3001 in Cassderma RX.

TheStreet. C-Suite Advisors World Health Organization Says

“We’re in a Wound Pandemic”

According to the WHO and the National Institutes of Health, there is an unmet global need for effective wound healing.

According to the organizations, there is a critical need to improve the way we treat wounds around the world. Statistics from the National Council for Biotechnology Information, World Health Organization, and National Institutes of Health, state there is a “Worldwide pandemic” affecting 6.5 million patients in the U.S. alone, costing $25 billion annually, and rapidly growing due to the increase in healthcare costs, aging population, and the sharp rise obesity and diabetes.

In hospitals alone, 1,000 people per week die due to pressure ulcers. In diabetes patients, 84% of amputations are attributed to open wounds. Unsanitary and/or combat conditions contribute to this. Other factors include immune deficiency and malnutrition.

TYPICAL WOUND TREATMENT

Recalcitrant wounds generally do not respond to traditional wound therapies.

A wound is defined as a break in the continuity of the skin, caused by traumatic injury, such as a burn, cut, or scrape, exposure to excessively hot or cold temperatures, chemical damage due to acid, alkaline burns, and damage by radiation.

In normal settings, prompt treatment will avoid complications such as infection and inflammation. The usual and conservative methods of closing a wound include the application of various antibiotics and bandages or alternatively, the wound is closed by a surgical procedure of suturing the wound’s edges, grafting cultured skin, or by split skin grafts. The aim of all the above is to promote the growth of granulation tissue that may or may not follow promptly, depending on adequate blood supply bringing into the wound the nutrients that the cells need for growth.

By using similar nutrient media supplements, the milieu in the wound becomes moist and enriched with nutrients capable of supplying all the requirements the cells need to proliferate and grow into the wound space, creating a better environment for healing.
However, if the wound is infected or if the blood supply is insufficient for tissue growth and contamination overcomes the antiseptics, the healing process fails, and the wound becomes chronic. This is the case in most hospitals with pressure ulcers, unsanitary conditions, or underlying conditions, such as diabetes, venous insufficiency, or compromised immune system.

TESTING ALTERNATIVE WOUND CARE METHODS

Fortunately, there may be a better way. In a series of pre-clinical and clinical trials, Cassderma RX scientists used a formulation containing a serum-free cell culture nutrient medium supplemented with a non-steroidal anabolic hormone to successfully treat atrophic recalcitrant wounds.

This patented serum-free cell culture media supplement supplies the cells in the wound with the nutrients required for the healing process and physiological activity that promote the entry of glucose into cells, converting it to energy. This energy can be utilized for the regeneration of granulation tissues, which is necessary to treat recalcitrant chronic wounds.

For example, surgical procedures designed to heal wounds are only successful when the application of the graft is performed onto viable granulation tissue. The success of the graft is dependent on the proliferation of granulation tissue, which can be achieved only when an adequate micro-environment is created in the wound. As a result, the viability of the grafted tissue over the wound is limited by the availability of the materials for obtaining the success of the graft and the healing process.

This supplement is based on human cell culture technology that grows fibroblast and epithelial cells in culture. By using similar nutrient media supplements, the milieu in the wound becomes moist and enriched with nutrients capable of supplying all the requirements the cells need to proliferate and grow into the wound space, creating a better environment for healing.

LOOKING FORWARD WITH WOUND CARE

Currently, the only other option for treating chronic wounds is to keep changing the bandages with the hope of not getting the wound infected. Imagine if wounds could heal faster. Imagine the world of relief for all of those who are suffering from chronic open wounds. Imagine a faster recovery time after surgery.

As we are still in a global pandemic, we should also be aware of other forms of global ongoing struggles. But I am very hopeful and optimistic as the scientific community is making great strides and achievements each day towards solutions and cures for our greatest ailments, with the goal of providing a healthier, quality, and enjoyable life.

The original article appeared online in: World Health Organization Says We’re in a “Wound Pandemic” – The Street – CSQ
by Daniel Rastein Jun 9, 2022 – Founder Cassderma RX

https://www.thestreet.com/csuiteadvisors/health-and-wellness/daniel-rastein-csa-world-health-organization-says-were-in-aa-wound-pandemic

ABOUT TheStreet/C-Suite Advisors

TheStreet is a financial news and financial literacy outlet. Founded in 1996, the company went public in 1999 and was recently acquired by the Maven in 2019 for $16.5 million. The Street It is a subsidiary of the Arena Group. Located at www.TheStreet.com.

ABOUT CASSDERMA RX

Founded by David Navid Rastein, MD, MPH

Cassderma RX is one of the five separate medical technology portfolio projects financed by PFDMOF3001.

Cassderma Founder Dr. Daniel Rastien

Daniel N. Rastein has an extensive and distinguished background in research programmatic design and implementation to comply with local, state, federal, and international health and safety regulations. He has previously served as Chief Compliance Officer at RadCore Labs, LLC, Compliagent, Inc., and Beacon Behavioral Solutions / Evolve Treatment Centers, including having served for more than a decade as an FDA GLP Research Compliance Officer for Cedars-Sinai Medical Center. Daniel has also helped in the licensing, accreditation, and regulatory programs for Stanford Medical Center, Stanford Lucile Packard Children’s Hospital, Children’s Hospital Los Angeles, and the Children’s Oncology Group. Originally trained as a medical doctor, he decided to continue his studies and earned a Master’s in Public Health at UCLA. Daniel has achieved numerous certifications and designations in the compliance field, including the Healthcare Compliance Association (HCCA), Society of Quality Assurance (SQA), American Biological Safety Association (ABSA), and the British Association of Research Quality Assurance (BARQA). He is the Founder of Compliance and Regulatory of America / C.A.R.A. Consulting Corporation and is an industry expert in the field of governmental regulations, from CMS to OIG to FDA to USDA. Daniel has been integrally involved in designing regulatory standards in the development of numerous drugs and biomedical devices for cutting-edge manufacturing, research, medical, aerospace, and agriculture companies. He is a faculty member, adviser, and regular lecturer at the Institute for Medical Leadership, UCLA David Geffen School of Medicine, UCLA Fielding School of Public Health, and the USC International School of Regulatory Science.

OVERVIEW

Cassderma RX is the developer of an innovative pharmaceutical-grade topical gel that supports the rapid regeneration of tissue for atrophic recalcitrant wounds. The gel is based on a patented formulation that uses a serum-free, nutrient-rich medium supplemented with a non-steroidal anabolic hormone to stimulate and support the growth of connective tissue originating from a wound bed and its peripheral walls. The gel has been found to be effective in reducing the healing time on a broad spectrum of wound types including diabetic ulcers, pressure ulcers, burns, and surgical wounds. The formulation has even been found to be effective in treating persistent long-term wounds where other current methods of regeneration have been unsuccessful.

Wound treatment before and after shows marked restoration of tissue

Cassderma RX has completed its proof-of-concept and is now working on finalizing its formulation to begin the initial clinical trials needed for advancing its regulatory requirements. Based on the outcome of the trials, the company will seek FDA approval for an Investigational New Drug (IND) authorization to move forward with its commercialization process.

About PFD Capital Partners, INC

As a sponsor of fundraising efforts for the affiliated companies of the PFD family of companies, PFD Capital Partners, INC provides capital formulation, management, and portfolio administration services.

About PFD Capital Partners, LLC

A manager and vendor to the PFD Family Private Equity programs.

About PFD Management Opportunity Fund 3001, LLC

A medical account receivables finance fund offering a fixed rate return with additional equity participation in targeted new medical technology opportunities.